Promising results boost hopes for the new generation of obesity and diabetes treatments

Dubai - UAE

Novo Nordisk announced the preliminary results of the third phase of the REIMAGINE 5 and REDEFINE 9 studies evaluating the innovative once-weekly experimental drug Cagresima for weight management and type 2 diabetes. The results showed the drug's superiority in weight reduction and management of vital signs compared to available treatments and placebo doses.

Positive indicators in reducing weight and cumulative blood sugar levels

The results of the REIMAGINE 5 study showed that the drug “Cagresima” (1.0 mg/1.0 mg) was superior to the drug “Terzepatide” (5 mg) in weight loss, with an average rate of 12.4% compared to 9.1% for “Terzepatide”, in addition to achieving a reduction in the cumulative blood sugar rate by 1.71%. In the REDEFINE 9 study, the drug achieved a weight loss of 21.0% compared to 2.0% for placebo, with a significant improvement in systolic blood pressure, waist circumference and fat percentage.

A medical vision for a new generation of treatments
Commenting on the results of the clinical trials, Martin Holst-Lange, Executive Vice President and Head of Research and Development at Novo Nordisk, said: “The results achieved by Cagresima are encouraging, as they confirm the effectiveness of semaglutide and Cagrilintide. Cagresima is still a treatment under research, but these results strengthen our confidence in the potential of this treatment, add to the growing list of evidence about the role of the amylin compound, and contribute to renewing our determination to develop the new generation.” It is a treatment for obesity and type 2 diabetes.

Providing flexible options for managing obesity and diabetes

These data and preliminary results provide scientific evidence about the drug’s potential in providing treatment options that suit the individual needs of patients, and expand the areas of effectiveness, safety, and acceptance of approved drug strengths in the service of managing type 2 diabetes and combating obesity.